Vol. 22/No. 10 | Oncology Live®

May 26, 2021

During a recent OncLive Peer Exchange®, a panel of lymphoma experts discussed tafasitamab-cxix, polatuzumab vedotin-piiq, and selinexor, and how and when they use them for their patients with diffuse large B-cell lymphoma.

May 25, 2021

Dysregulated platelet-derived growth factor receptor signaling is implicated in a number of cancer types and is among the targets of many FDA-approved multikinase inhibitors.

May 24, 2021

Larotrectinib (Vitrakvi) has proved to be highly active in patients with thyroid cancer with NTRK gene fusions, exhibiting rapid and durable disease control.

May 21, 2021

Results of the National Lung Screening Trial demonstrated a 20% decrease in lung cancer mortality in individuals aged 55 to 74 years with a 30 pack-year smoking history using a low-dose computed tomography scan.

May 20, 2021

Although the United States is behind Europe in terms of biosimilars approved and launched, the FDA is adding more approvals each year—29 since 2014—and 73 additional biosimilar candidates are in clinical trials and/or under FDA review.

May 19, 2021

Providers and health care institutions want more real-world data on how patients respond to various biosimilar products, according to a varied panel of private practice, academic hospital, and group purchasing organization experts in a discussion at the Community Oncology Alliance virtual 2021 Community Oncology Conference in April.

May 18, 2021

Roy S. Herbst, MD, PhD, was inspired to become an oncologist during his first week as an MD/PhD candidate at Cornell University and The Rockefeller University, thanks in part to Ralph L. Nachman, MD, longtime chair of Weill Department of Medicine at Weill Cornell Medical College.

May 17, 2021

Investigators are evaluating the addition of nivolumab to standard neoadjuvant therapy in patients with high-risk, estrogen-receptor–positive/ HER2-negative breast cancer to determine whether the PD-1 immune checkpoint inhibitor can improve recurrence rates.

May 14, 2021

Opinion leaders provide a glimpse into the future of what approaches adopted during COVID-19 may persist in oncology after the pandemic ends.

May 14, 2021

Amitkumar Mehta, MD, the safety profile of liso-cel and how it is advancing the relapsed/refractory large B-cell lymphoma treatment paradigm.

May 13, 2021

Nikhil C. Munshi, MD, discusses how idecabtagene vicleucel has potentially marked the beginning of a new chapter for cellular therapy in multiple myeloma.

May 13, 2021

The challenges of assessing COVID-19 vaccines shows that events in the real world may differ from those of a formal objective scientific analysis, especially in a setting where such evaluations of necessity involve very small numbers.